<DOC>
	<DOCNO>NCT02571712</DOCNO>
	<brief_summary>A study evaluate long-term safety GANFORT® ( bimatoprost 0.03 % plus timolol 0.5 % ) Chinese patient open-angle glaucoma ocular hypertension insufficiently responsive topical beta-blocker prostaglandin analogue .</brief_summary>
	<brief_title>Safety GANFORT® Ophthalmic Solution Chinese Patients With Open-angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis openangle glaucoma ocular hypertension insufficiently responsive topical betablockers prostaglandin analogues one eye Is willing stop intraocular pressure ( IOP ) lower medication switch GANFORT® single agent affect eye ( ) . Reactive airway disease include bronchial asthma history bronchial asthma severe chronic obstructive pulmonary disease Sinus bradycardia , sick sinus syndrome , sinoatrial block , second third degree atrioventricular block , control pacemaker . Overt cardiac failure , cardiogenic shock .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>